nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—liver cancer—sarcoma	0.217	0.638	CtDrD
Sorafenib—kidney cancer—sarcoma	0.123	0.362	CtDrD
Sorafenib—FLT1—sarcoma	0.0814	0.26	CbGaD
Sorafenib—PDGFRB—sarcoma	0.0673	0.215	CbGaD
Sorafenib—PDGFRA—sarcoma	0.0656	0.209	CbGaD
Sorafenib—RALBP1—Vincristine—sarcoma	0.0526	0.277	CbGbCtD
Sorafenib—KDR—sarcoma	0.051	0.163	CbGaD
Sorafenib—KIT—sarcoma	0.0481	0.154	CbGaD
Sorafenib—RALBP1—Doxorubicin—sarcoma	0.0328	0.173	CbGbCtD
Sorafenib—CYP2B6—Thiotepa—sarcoma	0.0118	0.0625	CbGbCtD
Sorafenib—UGT1A1—Etoposide—sarcoma	0.0083	0.0438	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—sarcoma	0.00809	0.0427	CbGbCtD
Sorafenib—ABCG2—Mitoxantrone—sarcoma	0.00724	0.0382	CbGbCtD
Sorafenib—ABCC2—Vincristine—sarcoma	0.00551	0.0291	CbGbCtD
Sorafenib—ABCC2—Etoposide—sarcoma	0.00505	0.0266	CbGbCtD
Sorafenib—ABCG2—Vincristine—sarcoma	0.00498	0.0263	CbGbCtD
Sorafenib—ABCG2—Etoposide—sarcoma	0.00457	0.0241	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—sarcoma	0.00385	0.0203	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.00368	0.0194	CbGbCtD
Sorafenib—CYP3A7—Vincristine—sarcoma	0.00368	0.0194	CbGbCtD
Sorafenib—CYP3A4—Thiotepa—sarcoma	0.00364	0.0192	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—sarcoma	0.00345	0.0182	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—sarcoma	0.00312	0.0164	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—sarcoma	0.00292	0.0154	CbGbCtD
Sorafenib—CYP3A5—Vincristine—sarcoma	0.00276	0.0146	CbGbCtD
Sorafenib—ABCB1—Mitoxantrone—sarcoma	0.00261	0.0138	CbGbCtD
Sorafenib—CYP3A5—Etoposide—sarcoma	0.00253	0.0133	CbGbCtD
Sorafenib—CYP2C8—Etoposide—sarcoma	0.00243	0.0128	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—sarcoma	0.00219	0.0116	CbGbCtD
Sorafenib—CYP1A2—Etoposide—sarcoma	0.00188	0.00993	CbGbCtD
Sorafenib—ABCB1—Vincristine—sarcoma	0.0018	0.00948	CbGbCtD
Sorafenib—ABCB1—Etoposide—sarcoma	0.00165	0.00868	CbGbCtD
Sorafenib—CYP3A4—Mitoxantrone—sarcoma	0.00156	0.00825	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—sarcoma	0.00112	0.00592	CbGbCtD
Sorafenib—CYP3A4—Vincristine—sarcoma	0.00108	0.00568	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—sarcoma	0.00106	0.00558	CbGbCtD
Sorafenib—CYP3A4—Etoposide—sarcoma	0.000987	0.0052	CbGbCtD
Sorafenib—Regorafenib—TEK—sarcoma	0.000793	0.25	CrCbGaD
Sorafenib—CYP3A4—Doxorubicin—sarcoma	0.000673	0.00355	CbGbCtD
Sorafenib—Regorafenib—FLT1—sarcoma	0.000618	0.195	CrCbGaD
Sorafenib—Regorafenib—PDGFRB—sarcoma	0.000511	0.161	CrCbGaD
Sorafenib—Regorafenib—PDGFRA—sarcoma	0.000498	0.157	CrCbGaD
Sorafenib—Regorafenib—KDR—sarcoma	0.000387	0.122	CrCbGaD
Sorafenib—Regorafenib—KIT—sarcoma	0.000365	0.115	CrCbGaD
Sorafenib—CDK7—Idarubicin—Epirubicin—sarcoma	0.000204	0.173	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—sarcoma	0.000204	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—sarcoma	0.000204	0.173	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—sarcoma	0.000189	0.16	CbGdCrCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—sarcoma	0.000189	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—sarcoma	0.000189	0.16	CbGdCrCtD
Sorafenib—RALBP1—hematopoietic system—sarcoma	0.000139	0.00335	CbGeAlD
Sorafenib—PDGFRA—embryo—sarcoma	0.000138	0.00335	CbGeAlD
Sorafenib—RAF1—seminal vesicle—sarcoma	0.000138	0.00334	CbGeAlD
Sorafenib—EPHB6—seminal vesicle—sarcoma	0.000137	0.00332	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—sarcoma	0.000135	0.00327	CbGeAlD
Sorafenib—CDK7—liver—sarcoma	0.000135	0.00325	CbGeAlD
Sorafenib—TAOK2—liver—sarcoma	0.000133	0.00323	CbGeAlD
Sorafenib—FLT1—hematopoietic system—sarcoma	0.000132	0.00319	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—sarcoma	0.000131	0.00318	CbGeAlD
Sorafenib—RAF1—hematopoietic system—sarcoma	0.000131	0.00317	CbGeAlD
Sorafenib—BRAF—tendon—sarcoma	0.00013	0.00315	CbGeAlD
Sorafenib—KDR—myometrium—sarcoma	0.00013	0.00314	CbGeAlD
Sorafenib—MAP2K5—myometrium—sarcoma	0.00013	0.00314	CbGeAlD
Sorafenib—EPHA6—testis—sarcoma	0.00013	0.00314	CbGeAlD
Sorafenib—FGFR1—cardiac atrium—sarcoma	0.000127	0.00307	CbGeAlD
Sorafenib—FLT1—connective tissue—sarcoma	0.000127	0.00307	CbGeAlD
Sorafenib—CSF1R—myometrium—sarcoma	0.000127	0.00306	CbGeAlD
Sorafenib—FGFR1—uterus—sarcoma	0.000126	0.00306	CbGeAlD
Sorafenib—RAF1—connective tissue—sarcoma	0.000126	0.00305	CbGeAlD
Sorafenib—BRAF—bone marrow—sarcoma	0.000126	0.00305	CbGeAlD
Sorafenib—KDR—embryo—sarcoma	0.000125	0.00302	CbGeAlD
Sorafenib—STK10—hematopoietic system—sarcoma	0.000125	0.00302	CbGeAlD
Sorafenib—EPHX2—tendon—sarcoma	0.000124	0.00301	CbGeAlD
Sorafenib—PDGFRA—hematopoietic system—sarcoma	0.000124	0.00299	CbGeAlD
Sorafenib—ZAK—testis—sarcoma	0.000123	0.00297	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—sarcoma	0.000122	0.00295	CbGeAlD
Sorafenib—CSF1R—embryo—sarcoma	0.000122	0.00295	CbGeAlD
Sorafenib—HIPK3—testis—sarcoma	0.00012	0.00291	CbGeAlD
Sorafenib—MAP3K7—cardiac atrium—sarcoma	0.00012	0.00291	CbGeAlD
Sorafenib—FLT3—bone marrow—sarcoma	0.00012	0.00289	CbGeAlD
Sorafenib—MAP3K7—uterus—sarcoma	0.00012	0.00289	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—sarcoma	0.000119	0.00289	CbGeAlD
Sorafenib—PDGFRA—connective tissue—sarcoma	0.000119	0.00288	CbGeAlD
Sorafenib—MAP3K19—testis—sarcoma	0.000118	0.00285	CbGeAlD
Sorafenib—UGT1A1—hematopoietic system—sarcoma	0.000118	0.00285	CbGeAlD
Sorafenib—KDR—seminal vesicle—sarcoma	0.000117	0.00284	CbGeAlD
Sorafenib—MAP2K5—seminal vesicle—sarcoma	0.000117	0.00284	CbGeAlD
Sorafenib—MKNK2—cardiac atrium—sarcoma	0.000117	0.00282	CbGeAlD
Sorafenib—ZAK—liver—sarcoma	0.000116	0.00281	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—sarcoma	0.000116	0.00281	CbGeAlD
Sorafenib—MKNK2—uterus—sarcoma	0.000116	0.0028	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—sarcoma	0.000115	0.00279	CbGeAlD
Sorafenib—MKNK1—cardiac atrium—sarcoma	0.000115	0.00278	CbGeAlD
Sorafenib—KIT—myometrium—sarcoma	0.000115	0.00278	CbGeAlD
Sorafenib—CSF1R—seminal vesicle—sarcoma	0.000114	0.00277	CbGeAlD
Sorafenib—RAF1—skin of body—sarcoma	0.000114	0.00276	CbGeAlD
Sorafenib—HIPK3—liver—sarcoma	0.000114	0.00275	CbGeAlD
Sorafenib—EPHB6—skin of body—sarcoma	0.000113	0.00274	CbGeAlD
Sorafenib—TIE1—testis—sarcoma	0.000112	0.00272	CbGeAlD
Sorafenib—PDGFRB—myometrium—sarcoma	0.000112	0.00272	CbGeAlD
Sorafenib—KDR—hematopoietic system—sarcoma	0.000111	0.0027	CbGeAlD
Sorafenib—FGFR1—tendon—sarcoma	0.000111	0.00268	CbGeAlD
Sorafenib—KIT—embryo—sarcoma	0.000111	0.00268	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—sarcoma	0.000109	0.00263	CbGeAlD
Sorafenib—CSF1R—hematopoietic system—sarcoma	0.000109	0.00263	CbGeAlD
Sorafenib—FLT4—bone marrow—sarcoma	0.000109	0.00263	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—sarcoma	0.000108	0.00261	CbGeAlD
Sorafenib—PDGFRB—embryo—sarcoma	0.000108	0.00261	CbGeAlD
Sorafenib—BRAF—testis—sarcoma	0.000108	0.00261	CbGeAlD
Sorafenib—KDR—connective tissue—sarcoma	0.000107	0.0026	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—sarcoma	0.000107	0.00258	CbGeAlD
Sorafenib—TIE1—liver—sarcoma	0.000106	0.00257	CbGeAlD
Sorafenib—RET—lymphoid tissue—sarcoma	0.000105	0.00255	CbGeAlD
Sorafenib—RALBP1—cardiac atrium—sarcoma	0.000105	0.00255	CbGeAlD
Sorafenib—MAPK11—lymph node—sarcoma	0.000105	0.00254	CbGeAlD
Sorafenib—MAP3K7—tendon—sarcoma	0.000105	0.00254	CbGeAlD
Sorafenib—CSF1R—connective tissue—sarcoma	0.000105	0.00253	CbGeAlD
Sorafenib—RALBP1—uterus—sarcoma	0.000105	0.00253	CbGeAlD
Sorafenib—KIT—seminal vesicle—sarcoma	0.000104	0.00251	CbGeAlD
Sorafenib—CDK7—lymph node—sarcoma	0.000103	0.00249	CbGeAlD
Sorafenib—EPHX2—testis—sarcoma	0.000103	0.00249	CbGeAlD
Sorafenib—FLT3—testis—sarcoma	0.000102	0.00247	CbGeAlD
Sorafenib—TAOK2—lymph node—sarcoma	0.000102	0.00247	CbGeAlD
Sorafenib—BRAF—liver—sarcoma	0.000102	0.00247	CbGeAlD
Sorafenib—MKNK2—tendon—sarcoma	0.000102	0.00246	CbGeAlD
Sorafenib—MAP3K7—bone marrow—sarcoma	0.000102	0.00246	CbGeAlD
Sorafenib—AURKC—lymph node—sarcoma	0.000102	0.00246	CbGeAlD
Sorafenib—PDGFRB—seminal vesicle—sarcoma	0.000102	0.00246	CbGeAlD
Sorafenib—FLT1—cardiac atrium—sarcoma	0.0001	0.00242	CbGeAlD
Sorafenib—FLT1—uterus—sarcoma	9.96e-05	0.00241	CbGeAlD
Sorafenib—RAF1—cardiac atrium—sarcoma	9.95e-05	0.00241	CbGeAlD
Sorafenib—RET—tendon—sarcoma	9.91e-05	0.0024	CbGeAlD
Sorafenib—RAF1—uterus—sarcoma	9.9e-05	0.00239	CbGeAlD
Sorafenib—EPHB6—cardiac atrium—sarcoma	9.9e-05	0.00239	CbGeAlD
Sorafenib—KIT—hematopoietic system—sarcoma	9.88e-05	0.00239	CbGeAlD
Sorafenib—MKNK2—bone marrow—sarcoma	9.84e-05	0.00238	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—sarcoma	9.82e-05	0.00237	CbGeAlD
Sorafenib—EPHX2—liver—sarcoma	9.74e-05	0.00236	CbGeAlD
Sorafenib—MKNK1—bone marrow—sarcoma	9.72e-05	0.00235	CbGeAlD
Sorafenib—FLT3—liver—sarcoma	9.67e-05	0.00234	CbGeAlD
Sorafenib—PDGFRB—hematopoietic system—sarcoma	9.65e-05	0.00233	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—sarcoma	9.58e-05	0.00232	CbGeAlD
Sorafenib—KIT—connective tissue—sarcoma	9.51e-05	0.0023	CbGeAlD
Sorafenib—CSF1R—skin of body—sarcoma	9.46e-05	0.00229	CbGeAlD
Sorafenib—STK10—uterus—sarcoma	9.43e-05	0.00228	CbGeAlD
Sorafenib—PDGFRA—uterus—sarcoma	9.33e-05	0.00226	CbGeAlD
Sorafenib—FLT4—testis—sarcoma	9.29e-05	0.00225	CbGeAlD
Sorafenib—PDGFRB—connective tissue—sarcoma	9.29e-05	0.00225	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—sarcoma	9.28e-05	0.00225	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—sarcoma	9.23e-05	0.00223	CbGeAlD
Sorafenib—RALBP1—tendon—sarcoma	9.17e-05	0.00222	CbGeAlD
Sorafenib—FGFR1—testis—sarcoma	9.17e-05	0.00222	CbGeAlD
Sorafenib—CYP2C8—mammary gland—sarcoma	9.15e-05	0.00221	CbGeAlD
Sorafenib—ZAK—lymph node—sarcoma	8.91e-05	0.00216	CbGeAlD
Sorafenib—UGT1A9—liver—sarcoma	8.91e-05	0.00216	CbGeAlD
Sorafenib—HTR2B—myometrium—sarcoma	8.9e-05	0.00215	CbGeAlD
Sorafenib—RALBP1—bone marrow—sarcoma	8.89e-05	0.00215	CbGeAlD
Sorafenib—STK10—lymphoid tissue—sarcoma	8.79e-05	0.00213	CbGeAlD
Sorafenib—FLT4—liver—sarcoma	8.79e-05	0.00213	CbGeAlD
Sorafenib—FLT1—tendon—sarcoma	8.73e-05	0.00211	CbGeAlD
Sorafenib—HIPK3—lymph node—sarcoma	8.72e-05	0.00211	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—sarcoma	8.7e-05	0.0021	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—sarcoma	8.7e-05	0.0021	CbGeAlD
Sorafenib—MAP3K7—testis—sarcoma	8.68e-05	0.0021	CbGeAlD
Sorafenib—RAF1—tendon—sarcoma	8.68e-05	0.0021	CbGeAlD
Sorafenib—FGFR1—liver—sarcoma	8.67e-05	0.0021	CbGeAlD
Sorafenib—EPHB6—tendon—sarcoma	8.63e-05	0.00209	CbGeAlD
Sorafenib—KIT—skin of body—sarcoma	8.59e-05	0.00208	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—sarcoma	8.5e-05	0.00206	CbGeAlD
Sorafenib—MAP2K5—cardiac atrium—sarcoma	8.46e-05	0.00205	CbGeAlD
Sorafenib—KDR—cardiac atrium—sarcoma	8.46e-05	0.00205	CbGeAlD
Sorafenib—KDR—uterus—sarcoma	8.42e-05	0.00204	CbGeAlD
Sorafenib—MKNK2—testis—sarcoma	8.41e-05	0.00203	CbGeAlD
Sorafenib—RAF1—bone marrow—sarcoma	8.4e-05	0.00203	CbGeAlD
Sorafenib—PDGFRB—skin of body—sarcoma	8.39e-05	0.00203	CbGeAlD
Sorafenib—MKNK1—testis—sarcoma	8.31e-05	0.00201	CbGeAlD
Sorafenib—STK10—tendon—sarcoma	8.26e-05	0.002	CbGeAlD
Sorafenib—CSF1R—cardiac atrium—sarcoma	8.26e-05	0.002	CbGeAlD
Sorafenib—CSF1R—uterus—sarcoma	8.22e-05	0.00199	CbGeAlD
Sorafenib—MAP3K7—liver—sarcoma	8.21e-05	0.00198	CbGeAlD
Sorafenib—RET—testis—sarcoma	8.2e-05	0.00198	CbGeAlD
Sorafenib—PDGFRA—tendon—sarcoma	8.18e-05	0.00198	CbGeAlD
Sorafenib—TIE1—lymph node—sarcoma	8.15e-05	0.00197	CbGeAlD
Sorafenib—CYP2C9—mammary gland—sarcoma	8.13e-05	0.00197	CbGeAlD
Sorafenib—STK10—bone marrow—sarcoma	8e-05	0.00194	CbGeAlD
Sorafenib—MKNK2—liver—sarcoma	7.95e-05	0.00192	CbGeAlD
Sorafenib—MKNK1—liver—sarcoma	7.85e-05	0.0019	CbGeAlD
Sorafenib—KDR—lymphoid tissue—sarcoma	7.85e-05	0.0019	CbGeAlD
Sorafenib—BRAF—lymph node—sarcoma	7.82e-05	0.00189	CbGeAlD
Sorafenib—ABCC4—hematopoietic system—sarcoma	7.68e-05	0.00186	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—sarcoma	7.66e-05	0.00185	CbGeAlD
Sorafenib—RALBP1—testis—sarcoma	7.6e-05	0.00184	CbGeAlD
Sorafenib—EPHX2—lymph node—sarcoma	7.47e-05	0.00181	CbGeAlD
Sorafenib—KIT—uterus—sarcoma	7.46e-05	0.0018	CbGeAlD
Sorafenib—FLT3—lymph node—sarcoma	7.42e-05	0.00179	CbGeAlD
Sorafenib—CYP3A7—liver—sarcoma	7.41e-05	0.00179	CbGeAlD
Sorafenib—MAP2K5—tendon—sarcoma	7.38e-05	0.00178	CbGeAlD
Sorafenib—KDR—tendon—sarcoma	7.38e-05	0.00178	CbGeAlD
Sorafenib—PDGFRB—cardiac atrium—sarcoma	7.33e-05	0.00177	CbGeAlD
Sorafenib—PDGFRB—uterus—sarcoma	7.29e-05	0.00176	CbGeAlD
Sorafenib—FLT1—testis—sarcoma	7.23e-05	0.00175	CbGeAlD
Sorafenib—CSF1R—tendon—sarcoma	7.2e-05	0.00174	CbGeAlD
Sorafenib—RAF1—testis—sarcoma	7.18e-05	0.00174	CbGeAlD
Sorafenib—RALBP1—liver—sarcoma	7.18e-05	0.00174	CbGeAlD
Sorafenib—KDR—bone marrow—sarcoma	7.15e-05	0.00173	CbGeAlD
Sorafenib—EPHB6—testis—sarcoma	7.14e-05	0.00173	CbGeAlD
Sorafenib—CSF1R—bone marrow—sarcoma	6.97e-05	0.00169	CbGeAlD
Sorafenib—KIT—lymphoid tissue—sarcoma	6.95e-05	0.00168	CbGeAlD
Sorafenib—STK10—testis—sarcoma	6.84e-05	0.00165	CbGeAlD
Sorafenib—FLT1—liver—sarcoma	6.83e-05	0.00165	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—sarcoma	6.79e-05	0.00164	CbGeAlD
Sorafenib—RAF1—liver—sarcoma	6.79e-05	0.00164	CbGeAlD
Sorafenib—PDGFRA—testis—sarcoma	6.77e-05	0.00164	CbGeAlD
Sorafenib—FLT4—lymph node—sarcoma	6.74e-05	0.00163	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—sarcoma	6.73e-05	0.00163	CbGeAlD
Sorafenib—FGFR1—lymph node—sarcoma	6.65e-05	0.00161	CbGeAlD
Sorafenib—HTR2B—skin of body—sarcoma	6.64e-05	0.00161	CbGeAlD
Sorafenib—STK10—liver—sarcoma	6.47e-05	0.00156	CbGeAlD
Sorafenib—PDGFRA—liver—sarcoma	6.4e-05	0.00155	CbGeAlD
Sorafenib—CYP2C19—hematopoietic system—sarcoma	6.39e-05	0.00155	CbGeAlD
Sorafenib—PDGFRB—tendon—sarcoma	6.38e-05	0.00154	CbGeAlD
Sorafenib—KIT—bone marrow—sarcoma	6.33e-05	0.00153	CbGeAlD
Sorafenib—ABCG2—myometrium—sarcoma	6.32e-05	0.00153	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—sarcoma	6.3e-05	0.00152	CbGeAlD
Sorafenib—MAP3K7—lymph node—sarcoma	6.29e-05	0.00152	CbGeAlD
Sorafenib—PDGFRB—bone marrow—sarcoma	6.18e-05	0.0015	CbGeAlD
Sorafenib—MAP2K5—testis—sarcoma	6.11e-05	0.00148	CbGeAlD
Sorafenib—KDR—testis—sarcoma	6.11e-05	0.00148	CbGeAlD
Sorafenib—UGT1A1—liver—sarcoma	6.11e-05	0.00148	CbGeAlD
Sorafenib—MKNK2—lymph node—sarcoma	6.1e-05	0.00147	CbGeAlD
Sorafenib—MKNK1—lymph node—sarcoma	6.02e-05	0.00146	CbGeAlD
Sorafenib—CSF1R—testis—sarcoma	5.96e-05	0.00144	CbGeAlD
Sorafenib—RET—lymph node—sarcoma	5.95e-05	0.00144	CbGeAlD
Sorafenib—ABCC4—uterus—sarcoma	5.8e-05	0.0014	CbGeAlD
Sorafenib—MAP2K5—liver—sarcoma	5.77e-05	0.0014	CbGeAlD
Sorafenib—KDR—liver—sarcoma	5.77e-05	0.0014	CbGeAlD
Sorafenib—HTR2B—uterus—sarcoma	5.77e-05	0.0014	CbGeAlD
Sorafenib—ABCG2—seminal vesicle—sarcoma	5.71e-05	0.00138	CbGeAlD
Sorafenib—CSF1R—liver—sarcoma	5.64e-05	0.00136	CbGeAlD
Sorafenib—CYP2C8—hematopoietic system—sarcoma	5.58e-05	0.00135	CbGeAlD
Sorafenib—RALBP1—lymph node—sarcoma	5.51e-05	0.00133	CbGeAlD
Sorafenib—KIT—testis—sarcoma	5.41e-05	0.00131	CbGeAlD
Sorafenib—PDGFRB—testis—sarcoma	5.29e-05	0.00128	CbGeAlD
Sorafenib—FLT1—lymph node—sarcoma	5.24e-05	0.00127	CbGeAlD
Sorafenib—CYP1A2—hematopoietic system—sarcoma	5.22e-05	0.00126	CbGeAlD
Sorafenib—RAF1—lymph node—sarcoma	5.21e-05	0.00126	CbGeAlD
Sorafenib—Body temperature increased—Dactinomycin—sarcoma	5.2e-05	0.00116	CcSEcCtD
Sorafenib—EPHB6—lymph node—sarcoma	5.18e-05	0.00125	CbGeAlD
Sorafenib—Cardiac failure—Doxorubicin—sarcoma	5.15e-05	0.00115	CcSEcCtD
Sorafenib—Mood swings—Epirubicin—sarcoma	5.15e-05	0.00115	CcSEcCtD
Sorafenib—Loss of consciousness—Etoposide—sarcoma	5.13e-05	0.00115	CcSEcCtD
Sorafenib—KIT—liver—sarcoma	5.12e-05	0.00124	CbGeAlD
Sorafenib—Decreased appetite—Vincristine—sarcoma	5.11e-05	0.00114	CcSEcCtD
Sorafenib—Dyspnoea—Mitoxantrone—sarcoma	5.11e-05	0.00114	CcSEcCtD
Sorafenib—Cough—Etoposide—sarcoma	5.09e-05	0.00114	CcSEcCtD
Sorafenib—ABCC4—tendon—sarcoma	5.08e-05	0.00123	CbGeAlD
Sorafenib—Gastrointestinal disorder—Vincristine—sarcoma	5.08e-05	0.00113	CcSEcCtD
Sorafenib—Fatigue—Vincristine—sarcoma	5.07e-05	0.00113	CcSEcCtD
Sorafenib—HTR2B—tendon—sarcoma	5.06e-05	0.00122	CbGeAlD
Sorafenib—Dehydration—Epirubicin—sarcoma	5.05e-05	0.00113	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—sarcoma	5.05e-05	0.00113	CcSEcCtD
Sorafenib—Dyspepsia—Mitoxantrone—sarcoma	5.04e-05	0.00113	CcSEcCtD
Sorafenib—Hypertension—Etoposide—sarcoma	5.04e-05	0.00113	CcSEcCtD
Sorafenib—CYP3A5—hematopoietic system—sarcoma	5.03e-05	0.00122	CbGeAlD
Sorafenib—Constipation—Vincristine—sarcoma	5.03e-05	0.00112	CcSEcCtD
Sorafenib—Pain—Vincristine—sarcoma	5.03e-05	0.00112	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—sarcoma	5.03e-05	0.00112	CcSEcCtD
Sorafenib—CYP2B6—hematopoietic system—sarcoma	5e-05	0.00121	CbGeAlD
Sorafenib—PDGFRB—liver—sarcoma	5e-05	0.00121	CbGeAlD
Sorafenib—Dry skin—Epirubicin—sarcoma	4.98e-05	0.00111	CcSEcCtD
Sorafenib—Decreased appetite—Mitoxantrone—sarcoma	4.98e-05	0.00111	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—sarcoma	4.96e-05	0.00111	CcSEcCtD
Sorafenib—STK10—lymph node—sarcoma	4.96e-05	0.0012	CbGeAlD
Sorafenib—CYP2C9—hematopoietic system—sarcoma	4.95e-05	0.0012	CbGeAlD
Sorafenib—Hypokalaemia—Epirubicin—sarcoma	4.94e-05	0.0011	CcSEcCtD
Sorafenib—Fatigue—Mitoxantrone—sarcoma	4.94e-05	0.0011	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	4.94e-05	0.0011	CcSEcCtD
Sorafenib—ABCC4—bone marrow—sarcoma	4.92e-05	0.00119	CbGeAlD
Sorafenib—ABCC2—tendon—sarcoma	4.92e-05	0.00119	CbGeAlD
Sorafenib—Breast disorder—Epirubicin—sarcoma	4.91e-05	0.0011	CcSEcCtD
Sorafenib—PDGFRA—lymph node—sarcoma	4.91e-05	0.00119	CbGeAlD
Sorafenib—Pain—Mitoxantrone—sarcoma	4.9e-05	0.00109	CcSEcCtD
Sorafenib—Constipation—Mitoxantrone—sarcoma	4.9e-05	0.00109	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—sarcoma	4.89e-05	0.00109	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—sarcoma	4.89e-05	0.00109	CcSEcCtD
Sorafenib—Hypersensitivity—Thiotepa—sarcoma	4.89e-05	0.00109	CcSEcCtD
Sorafenib—Nasopharyngitis—Epirubicin—sarcoma	4.86e-05	0.00108	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—sarcoma	4.85e-05	0.00108	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vincristine—sarcoma	4.81e-05	0.00107	CcSEcCtD
Sorafenib—Gastritis—Epirubicin—sarcoma	4.81e-05	0.00107	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—sarcoma	4.79e-05	0.00107	CcSEcCtD
Sorafenib—Anaphylactic shock—Etoposide—sarcoma	4.76e-05	0.00106	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—sarcoma	4.76e-05	0.00106	CcSEcCtD
Sorafenib—Asthenia—Thiotepa—sarcoma	4.76e-05	0.00106	CcSEcCtD
Sorafenib—Infection—Etoposide—sarcoma	4.73e-05	0.00106	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—sarcoma	4.72e-05	0.00105	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—sarcoma	4.7e-05	0.00105	CcSEcCtD
Sorafenib—Pruritus—Thiotepa—sarcoma	4.69e-05	0.00105	CcSEcCtD
Sorafenib—Gastrointestinal pain—Mitoxantrone—sarcoma	4.68e-05	0.00105	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—sarcoma	4.68e-05	0.00104	CcSEcCtD
Sorafenib—Thrombocytopenia—Etoposide—sarcoma	4.66e-05	0.00104	CcSEcCtD
Sorafenib—Abdominal pain—Vincristine—sarcoma	4.65e-05	0.00104	CcSEcCtD
Sorafenib—Body temperature increased—Vincristine—sarcoma	4.65e-05	0.00104	CcSEcCtD
Sorafenib—Skin disorder—Etoposide—sarcoma	4.63e-05	0.00103	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—sarcoma	4.61e-05	0.00103	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—sarcoma	4.6e-05	0.00103	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—sarcoma	4.59e-05	0.00103	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—sarcoma	4.58e-05	0.00102	CcSEcCtD
Sorafenib—Urticaria—Mitoxantrone—sarcoma	4.55e-05	0.00102	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—sarcoma	4.54e-05	0.00101	CcSEcCtD
Sorafenib—Anorexia—Etoposide—sarcoma	4.54e-05	0.00101	CcSEcCtD
Sorafenib—Diarrhoea—Thiotepa—sarcoma	4.54e-05	0.00101	CcSEcCtD
Sorafenib—Abdominal pain—Mitoxantrone—sarcoma	4.53e-05	0.00101	CcSEcCtD
Sorafenib—Body temperature increased—Mitoxantrone—sarcoma	4.53e-05	0.00101	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	4.53e-05	0.00101	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	4.53e-05	0.00101	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—sarcoma	4.5e-05	0.00101	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—sarcoma	4.5e-05	0.001	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—sarcoma	4.45e-05	0.000993	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—sarcoma	4.43e-05	0.00099	CcSEcCtD
Sorafenib—MAP2K5—lymph node—sarcoma	4.43e-05	0.00107	CbGeAlD
Sorafenib—KDR—lymph node—sarcoma	4.43e-05	0.00107	CbGeAlD
Sorafenib—Neutropenia—Epirubicin—sarcoma	4.39e-05	0.00098	CcSEcCtD
Sorafenib—Dizziness—Thiotepa—sarcoma	4.39e-05	0.000979	CcSEcCtD
Sorafenib—CYP2B6—skin of body—sarcoma	4.35e-05	0.00105	CbGeAlD
Sorafenib—Dysphagia—Doxorubicin—sarcoma	4.35e-05	0.00097	CcSEcCtD
Sorafenib—Hypersensitivity—Vincristine—sarcoma	4.33e-05	0.000967	CcSEcCtD
Sorafenib—CSF1R—lymph node—sarcoma	4.32e-05	0.00105	CbGeAlD
Sorafenib—Pancreatitis—Doxorubicin—sarcoma	4.26e-05	0.000951	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—sarcoma	4.25e-05	0.000949	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—sarcoma	4.25e-05	0.000948	CcSEcCtD
Sorafenib—Hypersensitivity—Mitoxantrone—sarcoma	4.22e-05	0.000942	CcSEcCtD
Sorafenib—Asthenia—Vincristine—sarcoma	4.22e-05	0.000942	CcSEcCtD
Sorafenib—Vomiting—Thiotepa—sarcoma	4.22e-05	0.000941	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—sarcoma	4.21e-05	0.00094	CcSEcCtD
Sorafenib—ABCC4—testis—sarcoma	4.21e-05	0.00102	CbGeAlD
Sorafenib—Infestation NOS—Epirubicin—sarcoma	4.19e-05	0.000935	CcSEcCtD
Sorafenib—Infestation—Epirubicin—sarcoma	4.19e-05	0.000935	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—sarcoma	4.19e-05	0.000934	CcSEcCtD
Sorafenib—Rash—Thiotepa—sarcoma	4.18e-05	0.000934	CcSEcCtD
Sorafenib—Dermatitis—Thiotepa—sarcoma	4.18e-05	0.000933	CcSEcCtD
Sorafenib—Headache—Thiotepa—sarcoma	4.15e-05	0.000928	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—sarcoma	4.15e-05	0.000927	CcSEcCtD
Sorafenib—Rash—Dactinomycin—sarcoma	4.15e-05	0.000927	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—sarcoma	4.14e-05	0.000925	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—sarcoma	4.12e-05	0.000919	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—sarcoma	4.11e-05	0.000918	CcSEcCtD
Sorafenib—Asthenia—Mitoxantrone—sarcoma	4.11e-05	0.000917	CcSEcCtD
Sorafenib—Fatigue—Etoposide—sarcoma	4.11e-05	0.000917	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—sarcoma	4.1e-05	0.000916	CcSEcCtD
Sorafenib—ABCG2—uterus—sarcoma	4.1e-05	0.000991	CbGeAlD
Sorafenib—Jaundice—Epirubicin—sarcoma	4.08e-05	0.000911	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—sarcoma	4.08e-05	0.000911	CcSEcCtD
Sorafenib—ABCC2—testis—sarcoma	4.07e-05	0.000986	CbGeAlD
Sorafenib—Pain—Etoposide—sarcoma	4.07e-05	0.00091	CcSEcCtD
Sorafenib—Constipation—Etoposide—sarcoma	4.07e-05	0.00091	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—sarcoma	4.06e-05	0.000907	CcSEcCtD
Sorafenib—Diarrhoea—Vincristine—sarcoma	4.02e-05	0.000898	CcSEcCtD
Sorafenib—ABCC4—liver—sarcoma	3.98e-05	0.000963	CbGeAlD
Sorafenib—Hepatobiliary disease—Epirubicin—sarcoma	3.96e-05	0.000884	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—sarcoma	3.95e-05	0.000882	CcSEcCtD
Sorafenib—Nausea—Thiotepa—sarcoma	3.94e-05	0.000879	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—sarcoma	3.93e-05	0.000878	CcSEcCtD
Sorafenib—KIT—lymph node—sarcoma	3.92e-05	0.000949	CbGeAlD
Sorafenib—Diarrhoea—Mitoxantrone—sarcoma	3.92e-05	0.000875	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—sarcoma	3.91e-05	0.000873	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—sarcoma	3.9e-05	0.00087	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—sarcoma	3.9e-05	0.00087	CcSEcCtD
Sorafenib—Dizziness—Vincristine—sarcoma	3.89e-05	0.000868	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—sarcoma	3.87e-05	0.000865	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—sarcoma	3.87e-05	0.000865	CcSEcCtD
Sorafenib—ABCC2—liver—sarcoma	3.85e-05	0.000932	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	3.84e-05	0.000858	CcSEcCtD
Sorafenib—PDGFRB—lymph node—sarcoma	3.83e-05	0.000927	CbGeAlD
Sorafenib—Renal failure—Doxorubicin—sarcoma	3.81e-05	0.00085	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—sarcoma	3.8e-05	0.000848	CcSEcCtD
Sorafenib—Urticaria—Etoposide—sarcoma	3.78e-05	0.000845	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—sarcoma	3.78e-05	0.000843	CcSEcCtD
Sorafenib—CYP3A4—hematopoietic system—sarcoma	3.78e-05	0.000914	CbGeAlD
Sorafenib—Stomatitis—Doxorubicin—sarcoma	3.78e-05	0.000843	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—sarcoma	3.78e-05	0.000843	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—sarcoma	3.77e-05	0.000841	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—sarcoma	3.77e-05	0.000841	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—sarcoma	3.76e-05	0.000839	CcSEcCtD
Sorafenib—Vomiting—Vincristine—sarcoma	3.74e-05	0.000835	CcSEcCtD
Sorafenib—CYP2D6—hematopoietic system—sarcoma	3.72e-05	0.000899	CbGeAlD
Sorafenib—Urinary tract disorder—Epirubicin—sarcoma	3.71e-05	0.000829	CcSEcCtD
Sorafenib—Rash—Vincristine—sarcoma	3.71e-05	0.000828	CcSEcCtD
Sorafenib—Dermatitis—Vincristine—sarcoma	3.7e-05	0.000827	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—sarcoma	3.69e-05	0.000825	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—sarcoma	3.68e-05	0.000823	CcSEcCtD
Sorafenib—Headache—Vincristine—sarcoma	3.68e-05	0.000823	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—sarcoma	3.66e-05	0.000818	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—sarcoma	3.65e-05	0.000816	CcSEcCtD
Sorafenib—Vomiting—Mitoxantrone—sarcoma	3.64e-05	0.000813	CcSEcCtD
Sorafenib—Rash—Mitoxantrone—sarcoma	3.61e-05	0.000806	CcSEcCtD
Sorafenib—Dermatitis—Mitoxantrone—sarcoma	3.61e-05	0.000805	CcSEcCtD
Sorafenib—Headache—Mitoxantrone—sarcoma	3.59e-05	0.000801	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—sarcoma	3.55e-05	0.000793	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—sarcoma	3.52e-05	0.000852	CbGeAlD
Sorafenib—Hypersensitivity—Etoposide—sarcoma	3.51e-05	0.000784	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—sarcoma	3.5e-05	0.000782	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—sarcoma	3.5e-05	0.00078	CcSEcCtD
Sorafenib—Nausea—Vincristine—sarcoma	3.49e-05	0.00078	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—sarcoma	3.49e-05	0.000779	CcSEcCtD
Sorafenib—Flushing—Epirubicin—sarcoma	3.49e-05	0.000779	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—sarcoma	3.48e-05	0.000776	CcSEcCtD
Sorafenib—ABCG2—bone marrow—sarcoma	3.48e-05	0.000841	CbGeAlD
Sorafenib—Urinary tract disorder—Doxorubicin—sarcoma	3.43e-05	0.000767	CcSEcCtD
Sorafenib—Asthenia—Etoposide—sarcoma	3.42e-05	0.000763	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—sarcoma	3.42e-05	0.000763	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—sarcoma	3.41e-05	0.000761	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—sarcoma	3.41e-05	0.000761	CcSEcCtD
Sorafenib—Nausea—Mitoxantrone—sarcoma	3.4e-05	0.00076	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—sarcoma	3.4e-05	0.000758	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—sarcoma	3.39e-05	0.000756	CcSEcCtD
Sorafenib—Pruritus—Etoposide—sarcoma	3.37e-05	0.000752	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—sarcoma	3.36e-05	0.00075	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—sarcoma	3.32e-05	0.000742	CcSEcCtD
Sorafenib—CYP2C19—liver—sarcoma	3.31e-05	0.000801	CbGeAlD
Sorafenib—Mental disorder—Epirubicin—sarcoma	3.29e-05	0.000735	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—sarcoma	3.29e-05	0.000734	CcSEcCtD
Sorafenib—Erythema—Epirubicin—sarcoma	3.27e-05	0.000731	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—sarcoma	3.27e-05	0.000731	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—sarcoma	3.26e-05	0.000728	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—sarcoma	3.24e-05	0.000724	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—sarcoma	3.23e-05	0.000721	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—sarcoma	3.23e-05	0.000721	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—sarcoma	3.2e-05	0.000715	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—sarcoma	3.16e-05	0.000704	CcSEcCtD
Sorafenib—Dizziness—Etoposide—sarcoma	3.15e-05	0.000703	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—sarcoma	3.15e-05	0.000702	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—sarcoma	3.14e-05	0.000701	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—sarcoma	3.13e-05	0.0007	CcSEcCtD
Sorafenib—ABCB1—myometrium—sarcoma	3.11e-05	0.000753	CbGeAlD
Sorafenib—Arrhythmia—Doxorubicin—sarcoma	3.11e-05	0.000694	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—sarcoma	3.07e-05	0.000686	CcSEcCtD
Sorafenib—CYP2C8—testis—sarcoma	3.06e-05	0.000739	CbGeAlD
Sorafenib—ABCC4—lymph node—sarcoma	3.05e-05	0.000738	CbGeAlD
Sorafenib—Mental disorder—Doxorubicin—sarcoma	3.05e-05	0.00068	CcSEcCtD
Sorafenib—HTR2B—lymph node—sarcoma	3.04e-05	0.000734	CbGeAlD
Sorafenib—Vomiting—Etoposide—sarcoma	3.03e-05	0.000676	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—sarcoma	3.03e-05	0.000676	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—sarcoma	3.03e-05	0.000676	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—sarcoma	3.02e-05	0.000675	CcSEcCtD
Sorafenib—Rash—Etoposide—sarcoma	3e-05	0.000671	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—sarcoma	3e-05	0.00067	CcSEcCtD
Sorafenib—ABCB1—embryo—sarcoma	3e-05	0.000724	CbGeAlD
Sorafenib—Headache—Etoposide—sarcoma	2.98e-05	0.000666	CcSEcCtD
Sorafenib—ABCG2—testis—sarcoma	2.97e-05	0.000719	CbGeAlD
Sorafenib—Dysgeusia—Doxorubicin—sarcoma	2.96e-05	0.000662	CcSEcCtD
Sorafenib—ABCC2—lymph node—sarcoma	2.95e-05	0.000714	CbGeAlD
Sorafenib—Syncope—Epirubicin—sarcoma	2.93e-05	0.000655	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—sarcoma	2.93e-05	0.000654	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—sarcoma	2.91e-05	0.00065	CcSEcCtD
Sorafenib—CYP2C8—liver—sarcoma	2.89e-05	0.000699	CbGeAlD
Sorafenib—Loss of consciousness—Epirubicin—sarcoma	2.88e-05	0.000642	CcSEcCtD
Sorafenib—Cough—Epirubicin—sarcoma	2.86e-05	0.000637	CcSEcCtD
Sorafenib—Nausea—Etoposide—sarcoma	2.83e-05	0.000632	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—sarcoma	2.83e-05	0.000631	CcSEcCtD
Sorafenib—ABCB1—seminal vesicle—sarcoma	2.81e-05	0.00068	CbGeAlD
Sorafenib—ABCG2—liver—sarcoma	2.81e-05	0.000679	CbGeAlD
Sorafenib—Anaemia—Doxorubicin—sarcoma	2.8e-05	0.000625	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—sarcoma	2.79e-05	0.000622	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—sarcoma	2.79e-05	0.000622	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	2.77e-05	0.000618	CcSEcCtD
Sorafenib—CYP2B6—testis—sarcoma	2.74e-05	0.000663	CbGeAlD
Sorafenib—Dry mouth—Epirubicin—sarcoma	2.72e-05	0.000608	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—sarcoma	2.72e-05	0.000606	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—sarcoma	2.71e-05	0.000605	CcSEcCtD
Sorafenib—CYP1A2—liver—sarcoma	2.7e-05	0.000654	CbGeAlD
Sorafenib—ABCB1—hematopoietic system—sarcoma	2.67e-05	0.000647	CbGeAlD
Sorafenib—Anaphylactic shock—Epirubicin—sarcoma	2.67e-05	0.000596	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—sarcoma	2.66e-05	0.000594	CcSEcCtD
Sorafenib—Infection—Epirubicin—sarcoma	2.65e-05	0.000592	CcSEcCtD
Sorafenib—Cough—Doxorubicin—sarcoma	2.64e-05	0.00059	CcSEcCtD
Sorafenib—Shock—Epirubicin—sarcoma	2.63e-05	0.000587	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—sarcoma	2.62e-05	0.000585	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—sarcoma	2.61e-05	0.000584	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—sarcoma	2.61e-05	0.000584	CcSEcCtD
Sorafenib—CYP3A5—liver—sarcoma	2.61e-05	0.000631	CbGeAlD
Sorafenib—Skin disorder—Epirubicin—sarcoma	2.59e-05	0.000579	CcSEcCtD
Sorafenib—CYP2B6—liver—sarcoma	2.59e-05	0.000627	CbGeAlD
Sorafenib—Myalgia—Doxorubicin—sarcoma	2.58e-05	0.000575	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—sarcoma	2.58e-05	0.000575	CcSEcCtD
Sorafenib—CYP2C9—liver—sarcoma	2.57e-05	0.000621	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	2.56e-05	0.000571	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—sarcoma	2.55e-05	0.000568	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—sarcoma	2.52e-05	0.000563	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—sarcoma	2.47e-05	0.000552	CcSEcCtD
Sorafenib—Infection—Doxorubicin—sarcoma	2.45e-05	0.000548	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—sarcoma	2.43e-05	0.000543	CcSEcCtD
Sorafenib—Shock—Doxorubicin—sarcoma	2.43e-05	0.000543	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—sarcoma	2.42e-05	0.000541	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—sarcoma	2.42e-05	0.00054	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—sarcoma	2.4e-05	0.000536	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—sarcoma	2.38e-05	0.000532	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—sarcoma	2.36e-05	0.000526	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—sarcoma	2.35e-05	0.000525	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—sarcoma	2.32e-05	0.000518	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—sarcoma	2.31e-05	0.000515	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—sarcoma	2.3e-05	0.000514	CcSEcCtD
Sorafenib—Pain—Epirubicin—sarcoma	2.28e-05	0.00051	CcSEcCtD
Sorafenib—Constipation—Epirubicin—sarcoma	2.28e-05	0.00051	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.25e-05	0.000503	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—sarcoma	2.2e-05	0.000492	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—sarcoma	2.18e-05	0.000488	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—sarcoma	2.18e-05	0.000486	CcSEcCtD
Sorafenib—ABCG2—lymph node—sarcoma	2.15e-05	0.000521	CbGeAlD
Sorafenib—Decreased appetite—Doxorubicin—sarcoma	2.15e-05	0.00048	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—sarcoma	2.13e-05	0.000476	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—sarcoma	2.13e-05	0.000476	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—sarcoma	2.12e-05	0.000474	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—sarcoma	2.11e-05	0.000472	CcSEcCtD
Sorafenib—Pain—Doxorubicin—sarcoma	2.11e-05	0.000472	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—sarcoma	2.11e-05	0.000471	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—sarcoma	2.11e-05	0.000471	CcSEcCtD
Sorafenib—CYP2D6—testis—sarcoma	2.04e-05	0.000493	CbGeAlD
Sorafenib—Gastrointestinal pain—Doxorubicin—sarcoma	2.02e-05	0.000451	CcSEcCtD
Sorafenib—ABCB1—uterus—sarcoma	2.02e-05	0.000489	CbGeAlD
Sorafenib—Hypersensitivity—Epirubicin—sarcoma	1.97e-05	0.000439	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—sarcoma	1.96e-05	0.000438	CcSEcCtD
Sorafenib—CYP3A4—liver—sarcoma	1.96e-05	0.000473	CbGeAlD
Sorafenib—Body temperature increased—Doxorubicin—sarcoma	1.95e-05	0.000436	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—sarcoma	1.95e-05	0.000436	CcSEcCtD
Sorafenib—CYP2D6—liver—sarcoma	1.93e-05	0.000466	CbGeAlD
Sorafenib—Asthenia—Epirubicin—sarcoma	1.92e-05	0.000428	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—sarcoma	1.89e-05	0.000422	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—sarcoma	1.88e-05	0.000455	CbGeAlD
Sorafenib—Diarrhoea—Epirubicin—sarcoma	1.83e-05	0.000408	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—sarcoma	1.82e-05	0.000406	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—sarcoma	1.77e-05	0.000396	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—sarcoma	1.77e-05	0.000394	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—sarcoma	1.75e-05	0.00039	CcSEcCtD
Sorafenib—ABCB1—bone marrow—sarcoma	1.71e-05	0.000415	CbGeAlD
Sorafenib—Vomiting—Epirubicin—sarcoma	1.7e-05	0.000379	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—sarcoma	1.69e-05	0.000377	CcSEcCtD
Sorafenib—Rash—Epirubicin—sarcoma	1.68e-05	0.000376	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—sarcoma	1.68e-05	0.000376	CcSEcCtD
Sorafenib—Headache—Epirubicin—sarcoma	1.67e-05	0.000373	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—sarcoma	1.63e-05	0.000365	CcSEcCtD
Sorafenib—Nausea—Epirubicin—sarcoma	1.59e-05	0.000354	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—sarcoma	1.57e-05	0.000351	CcSEcCtD
Sorafenib—Rash—Doxorubicin—sarcoma	1.56e-05	0.000348	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—sarcoma	1.56e-05	0.000348	CcSEcCtD
Sorafenib—Headache—Doxorubicin—sarcoma	1.55e-05	0.000346	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—sarcoma	1.47e-05	0.000328	CcSEcCtD
Sorafenib—ABCB1—testis—sarcoma	1.47e-05	0.000354	CbGeAlD
Sorafenib—ABCB1—liver—sarcoma	1.39e-05	0.000335	CbGeAlD
Sorafenib—ABCB1—lymph node—sarcoma	1.06e-05	0.000257	CbGeAlD
Sorafenib—MAPK11—Immune System—KRAS—sarcoma	1.33e-06	2e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—HBA1—sarcoma	1.32e-06	1.99e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—sarcoma	1.32e-06	1.99e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MDM2—sarcoma	1.32e-06	1.99e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—sarcoma	1.32e-06	1.98e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—sarcoma	1.32e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FOXO1—sarcoma	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—IL2—sarcoma	1.31e-06	1.98e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PDGFRB—sarcoma	1.31e-06	1.97e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MDM2—sarcoma	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—sarcoma	1.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PDGFRA—sarcoma	1.29e-06	1.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EGFR—sarcoma	1.29e-06	1.94e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—sarcoma	1.29e-06	1.94e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—sarcoma	1.28e-06	1.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—sarcoma	1.28e-06	1.92e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EGFR—sarcoma	1.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EGFR—sarcoma	1.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—SRC—sarcoma	1.27e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—SRC—sarcoma	1.27e-06	1.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—sarcoma	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CTNNB1—sarcoma	1.26e-06	1.9e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KDR—sarcoma	1.26e-06	1.89e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—sarcoma	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—sarcoma	1.24e-06	1.87e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SRC—sarcoma	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PLCG1—sarcoma	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CREB1—sarcoma	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—SRC—sarcoma	1.24e-06	1.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—JUN—sarcoma	1.23e-06	1.85e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—sarcoma	1.22e-06	1.84e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CTNNB1—sarcoma	1.22e-06	1.83e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—sarcoma	1.22e-06	1.83e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—sarcoma	1.22e-06	1.83e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PLCG1—sarcoma	1.21e-06	1.82e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SRC—sarcoma	1.21e-06	1.82e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	1.21e-06	1.82e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EGFR—sarcoma	1.21e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EGFR—sarcoma	1.2e-06	1.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MDM2—sarcoma	1.2e-06	1.81e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MDM2—sarcoma	1.2e-06	1.81e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—sarcoma	1.2e-06	1.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—sarcoma	1.2e-06	1.8e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—sarcoma	1.2e-06	1.8e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—sarcoma	1.19e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—sarcoma	1.19e-06	1.79e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—sarcoma	1.19e-06	1.79e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—sarcoma	1.19e-06	1.79e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CREB1—sarcoma	1.18e-06	1.78e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—sarcoma	1.18e-06	1.77e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—sarcoma	1.18e-06	1.77e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EGFR—sarcoma	1.17e-06	1.76e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—sarcoma	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—sarcoma	1.16e-06	1.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—sarcoma	1.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—sarcoma	1.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—JUN—sarcoma	1.16e-06	1.74e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—sarcoma	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CTNNB1—sarcoma	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—JUN—sarcoma	1.15e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—SRC—sarcoma	1.14e-06	1.72e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MDM2—sarcoma	1.14e-06	1.72e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PLCG1—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CTNNB1—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MDM2—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—sarcoma	1.14e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—sarcoma	1.13e-06	1.71e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HBA1—sarcoma	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—sarcoma	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—EGFR—sarcoma	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PLCG1—sarcoma	1.13e-06	1.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CTNNB1—sarcoma	1.12e-06	1.69e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EGFR—sarcoma	1.11e-06	1.67e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—sarcoma	1.11e-06	1.67e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EGFR—sarcoma	1.11e-06	1.67e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—sarcoma	1.11e-06	1.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CREB1—sarcoma	1.1e-06	1.66e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—SRC—sarcoma	1.1e-06	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—sarcoma	1.1e-06	1.65e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1.09e-06	1.63e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KDR—sarcoma	1.09e-06	1.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EGFR—sarcoma	1.08e-06	1.63e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—sarcoma	1.08e-06	1.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—sarcoma	1.07e-06	1.62e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—sarcoma	1.07e-06	1.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—sarcoma	1.07e-06	1.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—sarcoma	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EGFR—sarcoma	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—EGFR—sarcoma	1.06e-06	1.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—sarcoma	1.05e-06	1.58e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—sarcoma	1.05e-06	1.58e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—sarcoma	1.05e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—sarcoma	1.05e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—JUN—sarcoma	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—JUN—sarcoma	1.04e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SRC—sarcoma	1.04e-06	1.56e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.04e-06	1.56e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CTNNB1—sarcoma	1.04e-06	1.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—sarcoma	1.03e-06	1.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SRC—sarcoma	1.03e-06	1.55e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—sarcoma	1.03e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.02e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—sarcoma	1.02e-06	1.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—sarcoma	1.02e-06	1.54e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—sarcoma	1.02e-06	1.53e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—sarcoma	1.02e-06	1.53e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—sarcoma	1.02e-06	1.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—SRC—sarcoma	1.02e-06	1.53e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.02e-06	1.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—sarcoma	1.01e-06	1.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—sarcoma	1e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—sarcoma	1e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—sarcoma	1e-06	1.51e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—sarcoma	1e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EGFR—sarcoma	1e-06	1.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—sarcoma	9.99e-07	1.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—sarcoma	9.98e-07	1.5e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—sarcoma	9.93e-07	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—JUN—sarcoma	9.91e-07	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—sarcoma	9.91e-07	1.49e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—sarcoma	9.9e-07	1.49e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—JUN—sarcoma	9.89e-07	1.49e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—sarcoma	9.84e-07	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	9.81e-07	1.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—sarcoma	9.78e-07	1.47e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MDM2—sarcoma	9.77e-07	1.47e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—sarcoma	9.68e-07	1.46e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PLCG1—sarcoma	9.66e-07	1.45e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EGFR—sarcoma	9.65e-07	1.45e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—sarcoma	9.65e-07	1.45e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CREB1—sarcoma	9.53e-07	1.43e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—sarcoma	9.45e-07	1.42e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—sarcoma	9.42e-07	1.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SRC—sarcoma	9.37e-07	1.41e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SRC—sarcoma	9.37e-07	1.41e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—sarcoma	9.31e-07	1.4e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—sarcoma	9.22e-07	1.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—sarcoma	9.16e-07	1.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MDM2—sarcoma	9.13e-07	1.37e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—sarcoma	9.12e-07	1.37e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—sarcoma	9.12e-07	1.37e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—sarcoma	9.12e-07	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—EGFR—sarcoma	9.12e-07	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—sarcoma	9.12e-07	1.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—sarcoma	9.11e-07	1.37e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EGFR—sarcoma	9.11e-07	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—sarcoma	9.08e-07	1.37e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EGFR—sarcoma	9.02e-07	1.36e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—sarcoma	9.01e-07	1.36e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—sarcoma	9.01e-07	1.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—sarcoma	8.94e-07	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—sarcoma	8.93e-07	1.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EGFR—sarcoma	8.91e-07	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—sarcoma	8.91e-07	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—JUN—sarcoma	8.91e-07	1.34e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—sarcoma	8.89e-07	1.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SRC—sarcoma	8.89e-07	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SRC—sarcoma	8.87e-07	1.33e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	8.84e-07	1.33e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—sarcoma	8.78e-07	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—sarcoma	8.73e-07	1.31e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HBA1—sarcoma	8.73e-07	1.31e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—sarcoma	8.73e-07	1.31e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—sarcoma	8.7e-07	1.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—sarcoma	8.66e-07	1.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	8.64e-07	1.3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—sarcoma	8.62e-07	1.3e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—sarcoma	8.6e-07	1.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—sarcoma	8.55e-07	1.29e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—sarcoma	8.53e-07	1.28e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—sarcoma	8.52e-07	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—sarcoma	8.51e-07	1.28e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—sarcoma	8.5e-07	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—sarcoma	8.49e-07	1.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—sarcoma	8.48e-07	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—sarcoma	8.43e-07	1.27e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—sarcoma	8.42e-07	1.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—sarcoma	8.39e-07	1.26e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—sarcoma	8.39e-07	1.26e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—sarcoma	8.21e-07	1.24e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—sarcoma	8.21e-07	1.24e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—sarcoma	8.16e-07	1.23e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—sarcoma	8.03e-07	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—sarcoma	7.99e-07	1.2e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—sarcoma	7.97e-07	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—sarcoma	7.96e-07	1.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—sarcoma	7.95e-07	1.2e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—sarcoma	7.94e-07	1.19e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MDM2—sarcoma	7.88e-07	1.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—sarcoma	7.88e-07	1.19e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—sarcoma	7.79e-07	1.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	7.78e-07	1.17e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—sarcoma	7.77e-07	1.17e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—sarcoma	7.76e-07	1.17e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—sarcoma	7.76e-07	1.17e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—sarcoma	7.75e-07	1.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—sarcoma	7.69e-07	1.16e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—sarcoma	7.65e-07	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—sarcoma	7.62e-07	1.15e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—sarcoma	7.57e-07	1.14e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLCG1—sarcoma	7.45e-07	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—sarcoma	7.42e-07	1.12e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—sarcoma	7.36e-07	1.11e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—sarcoma	7.34e-07	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—sarcoma	7.33e-07	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—sarcoma	7.32e-07	1.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—sarcoma	7.31e-07	1.1e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—sarcoma	7.24e-07	1.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—sarcoma	7.16e-07	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—sarcoma	7.16e-07	1.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—sarcoma	7.12e-07	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—sarcoma	7.04e-07	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—sarcoma	7e-07	1.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—sarcoma	6.94e-07	1.04e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—sarcoma	6.89e-07	1.04e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—sarcoma	6.89e-07	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—sarcoma	6.87e-07	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—sarcoma	6.85e-07	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—sarcoma	6.85e-07	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—sarcoma	6.83e-07	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—sarcoma	6.8e-07	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—sarcoma	6.68e-07	1e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—sarcoma	6.61e-07	9.95e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—sarcoma	6.59e-07	9.92e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—sarcoma	6.59e-07	9.92e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—sarcoma	6.54e-07	9.84e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—sarcoma	6.53e-07	9.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—sarcoma	6.38e-07	9.6e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—sarcoma	6.31e-07	9.49e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—sarcoma	6.26e-07	9.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—sarcoma	6.24e-07	9.39e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—sarcoma	6.24e-07	9.39e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—sarcoma	6.15e-07	9.25e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—sarcoma	5.99e-07	9.01e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—sarcoma	5.91e-07	8.9e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—sarcoma	5.9e-07	8.87e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—sarcoma	5.88e-07	8.84e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—sarcoma	5.62e-07	8.46e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—sarcoma	5.61e-07	8.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—sarcoma	5.51e-07	8.29e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—sarcoma	5.39e-07	8.1e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—sarcoma	5.36e-07	8.07e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—sarcoma	5.24e-07	7.88e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—sarcoma	5.09e-07	7.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—sarcoma	5.01e-07	7.54e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—sarcoma	4.52e-07	6.8e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—sarcoma	4.33e-07	6.51e-06	CbGpPWpGaD
